8 Results for "

heterozygous

" in MedChemExpress (MCE) Product Catalog:
Products (8)

8 Results for "heterozygous" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-137516
CAS No.: 2502156-03-6
Purity:  98.16%
Target:  

PROTACs Ras

Research Areas:  

Cancer

LC-2 is a potent and first-in-class von Hippel-Lindau-based PROTAC capable of degrading endogenous KRAS G12C, with DC50s between 0.25 and 0.76 μM . LC-2 covalently binds KRAS G12C with a MRTX849 warhead and recruits the E3 ligase VHL, inducing rapid and sustained KRAS G12C degradation leading to suppression of MAPK signaling in both homozygous and heterozygous KRAS G12C cell lines .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-155539
CAS No.: 2916371-59-8
Purity:  99.17%
Research Areas:  

Inflammation/Immunology

Cisd2 agonist 2 (compound 6) is a Cisd2 activator (EC50=191 nM), and Cisd2 levels are associated with non-alcoholic fatty liver disease (NAFLD). Cisd2 agonist 2 has no significant in vivo toxicity in Cisd2hKO-het mice (heterozygous hepatocyte-specific Cisd2 knockout). Cisd2 (CDGSH iron sulfur domain 2) is a zinc finger protein that is mainly localized in the endoplasmic reticulum or mitochondrial membrane. Cisd2 participates in mitochondrial function by forming homodimers containing two redox-active 2Fe-2S clusters .
loading...
    loading...
Cat. No.: HY-P99822
CAS No.: 2361290-85-7
Synonyms: SHR-1209

Target:  

PCSK9

Research Areas:  

Metabolic Disease

Recaticimab (SHR-1209) is a humanized IgG1 mAb that selectively targets PCSK9. Recaticimab reduces low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), triglyceride (TG), and lipoprotein(a) levels. Recaticimab can be used for hyperlipidemia research .
loading...
    loading...
Cat. No.: HY-B1112
CAS No.: 333-36-8
Synonyms: Bis(2,2,2-trifluoroethyl) ether; Flurothyl
Target:  

GABA Receptor

Research Areas:  

Neurological Disease

Fluorothyl (Bis (2,2,2-trifluoroethyl) ether; Flurothyl) is a GABAA receptor modulator and epileptogenic agent. Fluorothyl induces generalized epilepsy in mice. Fluorothyl is used for epilepsy research .
loading...
    loading...
Cat. No.: HY-173349
CAS No.: 3120102-92-0
Target:  

PARP

Research Areas:  

Cancer

TDI-012804 is a TNKS2 inhibitor that selectively inhibits intracellular endogenous TNKS2 protein. TDI-012804 increases the expression of AXIN1 protein in cells that are heterozygous (Tnks1HET) and completely knocks out (Tnks1KO) for TNKS1. TDI-012804 inhibits the proliferation of ApcQ1405X/Tnks1KO organoids (EC50 of 59.1 nM) and is selectively toxic to Tnks1KO AKP-G12D and AKP-G13D organoids .
loading...
    loading...
Cat. No.: HY-P11092
Target:  

Endogenous Metabolite

Research Areas:  

Neurological Disease

TLQP-62 (mouse,rat) is a secreted C-terminal peptide that can be derived from protein VGF. TLQP-62 activates the BDNF-TrkB signaling pathway, inducing acute, transient phosphorylation of TrkB receptor and downstream CREB (Ser133) phosphorylation. TLQP-62 demonstrates excellent efficacy in promoting long-term fear memory formationin wild-type mice and reversing memory impairment in VGF heterozygous knock-out mice. TLQP-62 can be used for the study of memory-related neurological disorders (e.g., Alzheimer’s disease, frontotemporal dementia) .
loading...
    loading...
Cat. No.: HY-W1126955
CAS No.: 2861205-06-1
Synonyms: MK-0616 decanoate
Target:  

PCSK9

Enlicitide (MK-0616) decanoate is an orally active macrocyclic peptide PCSK9 inhibitor. Enlicitide decanoate binds to PCSK9, blocks its interaction with low-density lipoprotein receptor (LDLR), and enhances hepatic clearance of LDL-C. Enlicitide decanoate reduces atherogenic lipoproteins, including non-HDL cholesterol, apolipoprotein B, and lipoprotein (a). Enlicitide decanoate is applicable to research related to hypercholesterolemia, heterozygous familial hypercholesterolemia, and atherosclerotic cardiovascular disease .
loading...
    loading...
Cat. No.: HY-182456
CAS No.: 1426319-74-5
Target:  

KMO

Research Areas:  

Neurological Disease

CHDI-340246 is an orally active kynurenine monooxygenase (KMO) inhibitor. CHDI-340246 blocks KMO activity, alters the metabolic flux of the kynurenine pathway, inhibits the production of 3-hydroxykynurenine and quinolinic acid, elevates the levels of kynurenine and kynurenic acid, and restores electrophysiological abnormalities in transgenic mouse models of Huntington's disease. CHDI-340246 can be used in studies related to Huntington's disease .
loading...
    loading...